Addressing the Clinical Lag in PsA Diagnosis and Treatment Among Underrepresented and Special Populations

Key Takeaways:

• Phenotypic variations in patients with darker skin phototypes (Fitzpatrick IV-VI) and atypical presentations (elevated CRP, dactylitis) delay diagnosis and accelerate irreversible structural damage.
• High metabolic burden and adipokine-driven inflammation in underrepresented cohorts can reduce the efficacy of DMARDs, leading to higher use of biologics such as IL-23 inhibitors.
• Socioeconomic and diagnostic barriers to initiating advanced therapy within the 6 to 12-month "window of opportunity" correlate with higher radiographic progression and functional disability.

The therapeutic landscape for psoriatic arthritis (PsA) has undergone a paradigm shift with the advent of IL-17A, IL-23, and JAK inhibitors. However, the translation of these clinical advancements into real-world outcomes remains non-uniform across different patient demographics.¹

A significant "clinical lag" – defined as the interval between symptom onset and the initiation of advanced systemic therapy – persists, particularly among underrepresented racial and ethnic groups, and patients in lower socioeconomic strata. Understanding the multifactorial drivers of this delay is essential to mitigating permanent joint damage and improving long-term functional outcomes.²

Pathophysiological and phenotypic variations

The diagnostic delay in PsA is often exacerbated by phenotypic variations that deviate from the "classic" presentations documented in historical cohorts, which were predominantly Caucasian. Research indicates that African American and Hispanic patients often present with higher markers of systemic inflammation (e.g., elevated C-reactive protein) and a greater burden of dactylitis and enthesitis at the time of diagnosis compared to their white counterparts.²

Furthermore, the clinical assessment of psoriasis – the primary cutaneous precursor to PsA – is frequently confounded by skin phototype. In darker skin tones (Fitzpatrick types IV-VI), the characteristic salmon-pink erythema may appear violaceous or hyperpigmented, leading to frequent misdiagnosis or underestimation of the Body Surface Area (BSA) involvement.³

This clinical oversight is critical, as the severity and extent of cutaneous involvement are known predictors for the development of inflammatory arthropathy.

Efficacy gap and structural determinants

Recent post-hoc analyses of Phase 3 clinical trials (e.g., DISCOVER-1 and SELECT-PsA) have begun to interrogate whether clinical trial efficacy translates across diverse demographics. While the molecular mechanisms of TNF-α or IL-17 inhibition appear consistent, the "real-world" ACR20/50/70 response rates often lag in underrepresented populations.⁴

Data suggests this disparity is not driven by intrinsic pharmacogenomic differences, but by a disproportionate burden of cardiometabolic comorbidities – specifically obesity, type 2 diabetes, and hypertension. These conditions act as active drivers of systemic inflammation rather than mere "background noise."²

For instance, excess adipose tissue functions as a pro-inflammatory endocrine organ, secreting adipokines that increase the total systemic "cytokine load." This competing inflammatory environment, coupled with an increased volume of distribution in patients with higher BMIs, can attenuate the response to DMARDs by effectively neutralizing the medication before clinical targets are met.²

Impact on structural progression

The clinical implication of diagnostic delay is the irreversible progression of erosive joint disease. The "window of opportunity" hypothesis in PsA posits that intervention within the first 6 to 12 months of symptom onset significantly increases the probability of achieving drug-free remission.¹

Current data illustrate that underrepresented patients are significantly less likely to be prescribed a bDMARD or targeted synthetic DMARD (tsDMARD) during this critical window. This therapeutic inertia often stems from a combination of provider bias, socioeconomic barriers to specialty care, disparate insurance mandates (e.g., "step therapy" requirements that favor antiquated conventional synthetic DMARDs over modern biologics), and other disparities.²

Strategies to help close this lag

To address these disparities and close the clinical lag, clinicians should adopt a more granular, data-driven approach to screening and management:^1,2,5

• Standardized screening in primary care – Implement validated tools like the PEST (Psoriasis Epidemiology Screening Tool) or EARP (Early Arthritis Rheumatoid Psoriatic) specifically in community clinics serving diverse populations.
• Comorbidity-adjusted selection – Prioritize therapies with robust data in patients with high BMI or metabolic syndrome. For example, IL-23 inhibitors have shown sustained efficacy regardless of weight in certain sub-analyses.
• Proactive imaging – In cases where physical exam findings are ambiguous due to skin pigmentation or high subcutaneous fat, utilize Musculoskeletal Ultrasound (MSUS) or MRI to detect subclinical enthesitis or synovitis.
• Socio-therapeutic navigation – Recognize that "non-compliance" is often a proxy for "lack of access" or lack of understanding and communication between doctors and patients. Clinicians must leverage PharmD-led specialty pharmacy programs to navigate the prior authorization landscape and ensure continuity of care.

A clinical imperative

The evolution of PsA management from symptomatic relief to "treat-to-target" strategies demands a more equitable application of clinical rigor. As the specialty moves toward personalized medicine, clinicians must account for the intersection of pathophysiology, phenotype, and social determinants of health.²

Closing the diagnostic and therapeutic lag in underrepresented populations is not merely a matter of health equity; it is a clinical imperative to prevent the accrual of physical disability and improve the quality of life across the entire patient spectrum.²